Trials / Completed
CompletedNCT04941755
A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
A Phase 1 Open-label, 2-Period Crossover Study to Assess the Effect of Acid-reducing Agent Famotidine on the Pharmacokinetics of BMS-986256 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the effect of gastric pH changes induced by famotidine on the drug levels of BMS-986256.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986256 | Specified dose on specified days |
| DRUG | Famotidine | Specified dose on specified days |
Timeline
- Start date
- 2021-06-25
- Primary completion
- 2021-09-24
- Completion
- 2021-09-24
- First posted
- 2021-06-28
- Last updated
- 2022-01-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04941755. Inclusion in this directory is not an endorsement.